BioStem Technologies, Inc.
BSEM
$15.05
$0.5223.59%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 3,443.55% | 3,565.17% | 1,139.39% | 141.25% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3,443.55% | 3,565.17% | 1,139.39% | 141.25% | -- |
| Cost of Revenue | 1,333.70% | 936.08% | 381.60% | 45.06% | -- |
| Gross Profit | 3,752.00% | 4,170.02% | 1,274.32% | 155.38% | -- |
| SG&A Expenses | 1,079.63% | 769.51% | 398.64% | 131.10% | -- |
| Depreciation & Amortization | -5.56% | -8.27% | -4.23% | -6.00% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1,058.90% | 750.75% | 384.81% | 120.92% | -- |
| Operating Income | 297.47% | 201.01% | 88.86% | -90.94% | -- |
| Income Before Tax | 266.30% | 179.67% | 65.98% | -50.88% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 216.64% | 148.14% | 51.01% | -50.88% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 217.13% | 148.75% | 50.77% | -49.21% | -- |
| EBIT | 297.47% | 201.01% | 88.86% | -90.94% | -- |
| EBITDA | 303.92% | 205.35% | 91.56% | -95.50% | -- |
| EPS Basic | 192.81% | 134.95% | 49.27% | -26.51% | -- |
| Normalized Basic EPS | 247.41% | 172.84% | 77.59% | -62.07% | -- |
| EPS Diluted | 164.39% | 116.83% | 38.34% | -27.26% | -- |
| Normalized Diluted EPS | 207.22% | 147.99% | 64.04% | -62.07% | -- |
| Average Basic Shares Outstanding | 21.60% | 20.37% | 18.06% | 17.61% | -- |
| Average Diluted Shares Outstanding | 53.75% | 44.24% | 32.44% | 17.61% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |